Protagenic Therapeutics Inc MBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.85
- Day Range
- €0.85–0.85
- 52-Week Range
- €0.70–1.99
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €3.75 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.protagenic.com
Valuation
|
Metric
|
MBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MBP
|
|---|---|
Quick Ratio | 5.43 |
Current Ratio | 5.53 |
Interest Coverage | −80.50 |
Quick Ratio
MBP
Profitability
|
Metric
|
MBP
|
|---|---|
Return on Assets (Normalized) | −87.65% |
Return on Equity (Normalized) | −108.33% |
Return on Invested Capital (Normalized) | −105.90% |
Return on Assets
MBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mtqqkxg | Tvnpwk | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xyccrlpml | Btvxs | $114.2 Bil | |||
| Moderna Inc
MRNA
| Byqpbbft | Gdngq | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Brdbfnfp | Gyvqd | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rnjlsnlq | Tfvw | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tcyxlcgsf | Wptnb | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dkqmbyw | Nmfpqxp | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Pzxwllgp | Wwzy | $12.8 Bil | |||
| Incyte Corp
INCY
| Nyxlcvl | Svpvv | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mffjpvspz | Hlccg | $12.2 Bil |